Cargando…

Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment

BACKGROUND AND AIMS: To sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Knott, Tanya, Creeden, James, Horbach, Benjamin, Rauch‐Zumbrägel, Maximiliane, Vat, Lidewij, Harnik, Helena, Maravic, Zorana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435831/
https://www.ncbi.nlm.nih.gov/pubmed/37599652
http://dx.doi.org/10.1002/hsr2.1428
_version_ 1785092192704921600
author Knott, Tanya
Creeden, James
Horbach, Benjamin
Rauch‐Zumbrägel, Maximiliane
Vat, Lidewij
Harnik, Helena
Maravic, Zorana
author_facet Knott, Tanya
Creeden, James
Horbach, Benjamin
Rauch‐Zumbrägel, Maximiliane
Vat, Lidewij
Harnik, Helena
Maravic, Zorana
author_sort Knott, Tanya
collection PubMed
description BACKGROUND AND AIMS: To sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the expectations of different stakeholders from themselves and each other regarding PM. METHODS: This collaborative qualitative study was initiated by the global multistakeholder consortium From Testing to Targeted Treatments (FT3). Structured interviews were conducted with participants from five stakeholder groups: patients/patient advocates, healthcare providers (HCPs), researchers, policymakers/regulators/payers and industry representatives. A broad reach across geography, roles, experiences, and disease areas was sought. Results were analyzed by grounded theory methodology. RESULTS: All stakeholders stated that optimal implementation of PM can only be achieved through collaboration; industry representatives were the biggest promoters of collaboration. Stakeholders agreed that PM should be implemented focusing on the patient's best interest; HCPs were seen as important gatekeepers for PM by interacting directly with patients, and policymakers/payers were perceived as the most important drivers of access to PM. Areas of misalignment included the role of industry in clinical trial design and in access to PM (perceived as important by patients, HCPs and policymakers but not by industry representatives), and the stakeholders responsible for elaborating guidelines on PM use (patients indicated policymakers, while researchers indicated themselves). Priorities for optimal PM implementation and suggested actions included the need for enhancing high‐level policy focus, improving genomic literacy, optimizing the health technology assessment for PM, advocating for equitable access, promoting collaboration between industry and other stakeholder groups and development of reliable research standards. CONCLUSION: Stakeholder expectations revealed in this study suggested that no stakeholder group can drive change on its own; a global, multistakeholder collaborative approach that brings together current programs and best practices to support universal access to PM is needed.
format Online
Article
Text
id pubmed-10435831
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-104358312023-08-19 Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment Knott, Tanya Creeden, James Horbach, Benjamin Rauch‐Zumbrägel, Maximiliane Vat, Lidewij Harnik, Helena Maravic, Zorana Health Sci Rep Original Research BACKGROUND AND AIMS: To sustainably address challenges in implementing precision medicine (PM), coordinated efforts of different stakeholders are required. Understanding their expectations represents a first key step toward aligning on future actions and strategies. Here, we aimed to explore the expectations of different stakeholders from themselves and each other regarding PM. METHODS: This collaborative qualitative study was initiated by the global multistakeholder consortium From Testing to Targeted Treatments (FT3). Structured interviews were conducted with participants from five stakeholder groups: patients/patient advocates, healthcare providers (HCPs), researchers, policymakers/regulators/payers and industry representatives. A broad reach across geography, roles, experiences, and disease areas was sought. Results were analyzed by grounded theory methodology. RESULTS: All stakeholders stated that optimal implementation of PM can only be achieved through collaboration; industry representatives were the biggest promoters of collaboration. Stakeholders agreed that PM should be implemented focusing on the patient's best interest; HCPs were seen as important gatekeepers for PM by interacting directly with patients, and policymakers/payers were perceived as the most important drivers of access to PM. Areas of misalignment included the role of industry in clinical trial design and in access to PM (perceived as important by patients, HCPs and policymakers but not by industry representatives), and the stakeholders responsible for elaborating guidelines on PM use (patients indicated policymakers, while researchers indicated themselves). Priorities for optimal PM implementation and suggested actions included the need for enhancing high‐level policy focus, improving genomic literacy, optimizing the health technology assessment for PM, advocating for equitable access, promoting collaboration between industry and other stakeholder groups and development of reliable research standards. CONCLUSION: Stakeholder expectations revealed in this study suggested that no stakeholder group can drive change on its own; a global, multistakeholder collaborative approach that brings together current programs and best practices to support universal access to PM is needed. John Wiley and Sons Inc. 2023-08-17 /pmc/articles/PMC10435831/ /pubmed/37599652 http://dx.doi.org/10.1002/hsr2.1428 Text en © 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Knott, Tanya
Creeden, James
Horbach, Benjamin
Rauch‐Zumbrägel, Maximiliane
Vat, Lidewij
Harnik, Helena
Maravic, Zorana
Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title_full Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title_fullStr Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title_full_unstemmed Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title_short Stakeholders' expectations of precision medicine: A qualitative study to identify areas of (mis)alignment
title_sort stakeholders' expectations of precision medicine: a qualitative study to identify areas of (mis)alignment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435831/
https://www.ncbi.nlm.nih.gov/pubmed/37599652
http://dx.doi.org/10.1002/hsr2.1428
work_keys_str_mv AT knotttanya stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT creedenjames stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT horbachbenjamin stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT rauchzumbragelmaximiliane stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT vatlidewij stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT harnikhelena stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment
AT maraviczorana stakeholdersexpectationsofprecisionmedicineaqualitativestudytoidentifyareasofmisalignment